Lipirose-F 5 Tablet contains a combination of Fenofibrate 145 mg and Rosuvastatin 5 mg, which are lipid-lowering agents used to manage dyslipidemia and reduce the risk of cardiovascular disease. Fenofibrate, a fibric acid derivative, primarily acts by activating peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles, thereby effectively reducing serum triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin, a potent HMG-CoA reductase inhibitor, decreases cholesterol synthesis in the liver, resulting in lowered low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. The combination therapy is indicated for patients with mixed dyslipidemia or those who do not achieve adequate lipid control with monotherapy. Lipirose-F 5 is particularly beneficial in reducing the risk of atherosclerotic cardiovascular events by improving lipid profiles comprehensively. It should be used under medical supervision with regular monitoring of liver function tests, renal function, and lipid levels. Common side effects may include gastrointestinal disturbances, myalgia, and elevated liver enzymes. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in pregnancy and lactation. Adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.